Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | QUACK: patient-reported symptom burden as a prognostic factor

Kensei Yamaguchi • 2 Jul 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer Antibodies Cetuximab
QUACK

Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, outlines patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer, as evaluated in the Phase II QUACK study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Kensei Yamaguchi

3:02
Updates from DESTINY-Gastric 01
Kensei Yamaguchi • 2 Jul 2020
2:39
First line immunotherapy/chemotherapy in HER2- gastric cancer in Japan
Kensei Yamaguchi • 2 Jul 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals